GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Float Percentage Of Total Shares Outstanding

SELLAS Life Sciences Group (FRA:RXK3) Float Percentage Of Total Shares Outstanding : 99.81% (As of Dec. 15, 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SELLAS Life Sciences Group's float shares is 70.25 Mil. SELLAS Life Sciences Group's total shares outstanding is 70.38 Mil. SELLAS Life Sciences Group's float percentage of total shares outstanding is 99.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SELLAS Life Sciences Group's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SELLAS Life Sciences Group's Institutional Ownership is 6.68%.


SELLAS Life Sciences Group Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

SELLAS Life Sciences Group's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=70.25/70.38
=99.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SELLAS Life Sciences Group Business Description

Industry
Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group Headlines

No Headlines